Literature DB >> 15823724

Assessing the efficacy of antidepressants: the transactional paradigm.

U B Wolfaardt1, J R Reddon, A S Joyce.   

Abstract

Extant pharmacological literature seems to indicate that antidepressants are the most effective treatment for depression. However, there are flaws in the traditional paradigm for evaluating the efficacy of antidepressants. The traditional paradigm in pharmacology has adopted a biologically monistic causal structure, suggesting that the efficacy of antidepressants resides exclusively in biological pathways. The current paradigm in pharmacology has ignored the potential impact of psychological factors associated with the efficacy of antidepressants. This has occurred because psychological effects are seen as being a "paradigmatic anomaly," phenomena that are at odds with the traditional paradigm. Thus, the psychological factors associated with the administration of antidepressants have collectively been labeled as a "placebo effect" and discounted as a potential treatment pathway. However, empirical evidence suggests that the psychological factors, such as the formation of patient expectancies and a therapeutic alliance between physician and patient, increase the efficacy of antidepressants. Consequently, the current paper proposes the adoption of a transactional model that reflects the reciprocal interaction between psychological and biological factors associated with the efficacy of antidepressants.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823724     DOI: 10.1016/j.mehy.2004.12.024

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  Therapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels?

Authors:  Sigal Zilcha-Mano; Steven P Roose; Jacques P Barber; Bret R Rutherford
Journal:  Psychother Psychosom       Date:  2015-03-28       Impact factor: 17.659

2.  Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study).

Authors:  Wei Jiang; Ranga Krishnan; Maragatha Kuchibhatla; Michael S Cuffe; Carolyn Martsberger; Rebekka M Arias; Christopher M O'Connor
Journal:  Am J Cardiol       Date:  2011-02-15       Impact factor: 2.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.